Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Eikon Therapeutics, Inc. (EIKN)

Eikon Therapeutics updates corporate presentation with 2026 pipeline milestones

Neutral Impact 2 of 5 other Written later

On August 13, 2026, Eikon Therapeutics furnished an updated corporate presentation as Exhibit 99.1 to a Form 8-K under Regulation FD. The deck restates clinical data and pipeline timelines, including 2H 2026 Phase 2 data readouts for EIK1001 and an IND submission for EIK1006 projected by the end of 2026. The filing contains no financial results, guidance, or transaction terms.

Key points

  • Updated corporate presentation, labeled Q3 Company Update August 2026, furnished as Exhibit 99.1 and not deemed filed under the Exchange Act.
  • EIK1001 TeLuRide-005 nonsquamous NSCLC cohort showed an objective response rate of 55.6% (N=36 efficacy evaluable), with data as of May 4, 2026, presented at ASCO 2026.
  • EIK1003 monotherapy showed a 14.3% objective response rate (7/49), and 24.5% (13/53) in combination with paclitaxel, in Phase 1/2 data as of May 4, 2026.
  • EIK1006 (AR) IND submission is projected by the end of 2026.

The filing

CompanyEikon Therapeutics, Inc. (EIKN)
Form8-K, current report
Filed with the SECAug 13, 2026, 8:44 PM ET
Accession number0001193125-26-349936

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.